Preparing Performance Validation Documentation for Overseas Registration of IVD Products

How Should Performance Validation Documentation Be Prepared for Overseas Registration of IVD Products?

Performance validation documentation is the core of the technical file for overseas registration of IVD products and directly influences the review outcome. Manufacturers should first determine whether the product falls under the medical device regulatory scope of the target country (e.g., FDA, CE IVDR, NMPA, GHWP member states), and then select the appropriate registration pathway (self-assessment, third-party notified body, or competent authority review) based on the risk class (A/B/C/D or Class I/II/III). Key steps include conducting a reusability assessment of existing documentation from NMPA, CE, FDA, ISO 13485, or MDSAP programs, with a particular focus on whether the analytical performance validation data from domestic registration (e.g., precision, sensitivity, specificity, linearity, interference, stability) meet the target country's requirements.

Common risks include differences in reference standards (e.g., WHO standards versus local reference materials), sample type and matrix effects, reagent lot-to-lot consistency, and clinical evaluation strategy (e.g., acceptable non-inferiority margins, positive/negative percent agreement). For multi-country registrations (e.g., Southeast Asia, Middle East, Latin America), it is recommended to prepare a Common Technical Document (CTD) format and adjust localization requirements on a country-by-country basis, such as language translation, epidemiological context, and regulatory expectations. In addition, the local agent or authorized representative must assume substantive review responsibility for the performance validation documentation. Post-market changes (e.g., reagent formulation, calibrator value assignment) require timely updates to the performance validation report. Manufacturers should establish a performance validation data management system to ensure full lifecycle traceability.

Executive Summary

When preparing performance validation documentation for overseas registration of IVD products, the core is to determine whether existing data can support the target market application, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect the launch plan. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

Applicable Scenarios and Core Questions

Companies searching for this topic typically need to assess the reusability of their existing data for multiple markets, identify gaps in evidence, and understand the regulatory expectations of each target country. If entering GHWP member states or markets in Southeast Asia, the Middle East, or Latin America simultaneously, a single-country answer is insufficient. A more valuable approach is to create reusable versions of the core technical file, quality system certificates, performance validation data, clinical evidence, and labeling, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

• Step 1: Confirm regulatory scope. Determine whether the product falls under the medical device regulatory scope of the target country. For example, some countries impose special regulations on diagnostic software (SaMD) and companion diagnostics.
• Step 2: Determine the registration pathway by risk class. Low-risk products (e.g., Class A/Class I) may only need to meet general performance requirements, while high-risk products (e.g., Class D/Class III) require full analytical performance studies, clinical evidence, and risk management reports.
• Step 3: Assess reusability of existing documentation. If the product is already registered with NMPA, its analytical performance data may be partially accepted, but it is necessary to check whether reference standards, test methods, and sample sizes meet the target country's requirements.
• Step 4: Identify localization needs. For example, the FDA requires samples representative of the U.S. population; CE IVDR emphasizes the match between clinical performance evidence and intended use; some Southeast Asian countries may accept WHO standards but require local epidemiological data.
• Step 5: Plan supplementary testing. For missing parameters or non-compliant data, arrange new experiments and archive the results promptly.

Documentation and Evidence

Performance validation documentation typically includes the following core files:

• Analytical performance study protocols and reports (precision, accuracy, sensitivity, specificity, linearity, measuring range, interfering substances, cross-reactivity, hook effect, reagent stability, etc.)
• Calibrator and control material value assignment and traceability documentation
• Sample stability studies
• Matrix effect studies
• Comparison studies with other commercially available products
• If multi-center trials are involved, consistency analysis across centers
• For quantitative reagents, reportable range, inter-instrument reproducibility, reagent lot-to-lot variation, and calibrator lot-to-lot variation should be reported

Clinical performance evidence may be derived from prospective studies, retrospective sample banks, or existing literature data. For example, the FDA often requires comparison with a reference method or a similar marketed product, with calculation of positive percent agreement (PPA) and negative percent agreement (NPA). Under CE IVDR, high-risk products (List A/B) require clinical performance studies, and companion diagnostics must demonstrate impact on clinical treatment decisions. GHWP member states may accept clinical data from other markets, but ethnic difference analysis must be provided.

Common Mistakes

• Directly applying domestic registration data without considering target country reference standard differences (e.g., using Chinese national reference materials instead of WHO international standards).
• Sample sizes do not meet minimum statistical requirements, resulting in confidence intervals too wide to support claims.
• Confusing analytical performance with clinical performance, such as equating analytical sensitivity with clinical sensitivity.
• Incomplete stability data that do not cover real-world use conditions such as transport conditions, after opening, and freeze-thaw cycles.
• Lack of calibrator traceability statements or failure to use SI units for value assignment.
• Clinical performance studies do not consider target population prevalence or disease severity, leading to bias.
• Local agent not involved in review of validation documentation, making it difficult to answer technical questions during the review process.
• Post-market changes not reflected in updated performance validation reports, causing issues during license renewal or onsite inspections.

Manufacturer Preparation Checklist

• Confirm the target country's registration classification and performance validation requirements (refer to official guidance such as FDA CLSI EP series, CE IVDR Annex I and III).
• Compile a technical documentation checklist that includes all analytical performance study protocols, reports, and raw data.
• Review existing performance data against all required parameters of the target country; develop a supplementary testing plan for any gaps.
• When assigning calibrator values, confirm traceability to a reference measurement procedure or reference material and provide uncertainty.
• Prepare sample stability reports (at least shelf-life, transport simulation, and after-opening stability).
• If using non-standard sample types (e.g., plasma instead of serum), provide matrix effect study data.
• Collect clinical performance evidence (prospective, retrospective, literature) and ensure sample size meets statistical requirements.
• Establish a performance validation data management folder with version control, test records, and deviation handling records.
• Designate a local agent (or authorized representative) and provide a confirmation letter of their involvement in review.
• Develop a post-market performance monitoring plan, including lot release testing, complaint analysis, and periodic stability tracking.

AIMEILI Perspective

The most common misconception is that data approved in domestic registration can be directly transferred to overseas markets, while ignoring the special requirements of foreign regulators regarding reference standards, sample populations, and statistical methods. In the early stage of a project, a multi-country regulatory gap analysis should be prioritized—comparing the performance validation requirements of NMPA with those of each target country for the same product to identify missing and upgrade items. Reusable data primarily includes original experimental protocols, internal quality control data, and quality records under the ISO 13485 system. However, clinical performance reports, calibrator traceability documentation, and long-term stability data often require localized supplementation.

Local agent and certificate control are critical: the agent must have technical review capability to explain experimental design during the review; the certificate should belong to the manufacturer or its controlling entity to avoid supply disruptions due to agent changes. For multi-country registrations, it is recommended to prepare a globally unified technical document template (e.g., referencing the STED format), with core analytical performance modules common across markets, and only adding country-specific annexes (e.g., subgroup analysis for specific populations, official language translations). This reduces duplicate preparation and correction risks and shortens overall registration timelines.

Frequently Asked Questions

Must WHO standards be used as reference standards in performance validation?

Not necessarily, but most regulatory authorities require traceability of calibrator value assignment. If the target country recognizes ISO 17511 or CLSI EP32, a certified reference material may be used. For products without international standards, manufacturer internal standards can be used provided consistency is thoroughly verified.

Can clinical trials already conducted in China be used directly for overseas registration?

They may be partially accepted, but applicability must be assessed. FDA and CE IVDR require clinical data from the target population; if the Chinese patient population differs significantly from the target country population (e.g., genotype, prevalent strains), bridging studies or ethnic sensitivity analysis will be needed.

Do performance validation reports need to be translated into each country's language for multi-country registration?

Usually, the official language version of each country (e.g., English, Spanish, Arabic) must be submitted. It is recommended to maintain bilingual (Chinese-English) original reports, then employ professional medical translators for non-English countries and have the local agent review them to ensure terminology accuracy.

If the reagent formulation is changed after market launch, is performance validation required again?

Yes, any change that affects analytical performance (e.g., antibody source, formulation ingredients, calibrator value assignment) should be re-validated for at least critical parameters such as precision, accuracy, and stability, and the registration file must be updated. Significant changes may require prior regulatory approval.

Implementation Recommendations

In practice, companies should break down this issue into five tasks: regulatory determination, documentation preparation, evidence reuse, localization, and post-market maintenance—rather than having only one department temporarily compile files. This approach identifies documentation gaps earlier and aligns sales, R&D, quality, and regulatory teams on target country requirements.

If a company plans to enter multiple markets simultaneously, it is advisable to first form a unified core technical file and then supplement authorization, labeling, language, forms, and local agent documentation for different countries. The efficiency of multi-country registration often depends on the uniformity of the upfront documentation framework rather than the submission speed of a single country.

• First confirm whether the product falls under the medical device regulatory scope of the target country.
• Then confirm the risk class, registration pathway, and applicant entity.
• Verify that the technical file, quality system, and clinical evidence mutually support each other.
• Clarify the local agent, authorized representative, and certificate control.
• Establish a post-market change, renewal, and vigilance event maintenance mechanism.